About Anita

Anita Vasudevan works with a broad base of clients, including software, Internet of Things, edtech, cleantech, and medical device companies. She also routinely represents venture capital and corporate investors in financing transactions. She has substantial experience in a variety of corporate transactions, including venture capital financings, mergers and acquisitions and public offerings. Her practice also includes general business advising, including with respect to corporate securities, commercial agreements, and corporate governance matters.

View full bio

Experience

  • Cooley advises Inflammatix on $102M Series D Round

    • Cooley advises Inflammatix on $102M Series D Round

    March 24, 2021

    Cooley advised Inflammatix, a pioneering molecular diagnostics company, on its $102 million Series D funding round to support the development and commercialization of the company’s novel immune response diagnostics portfolio. D1 Capital Partners led the round, with participation from the company’s existing investors, including Northpond Ventures, Khosla Ventures, Think.Health, and OSF Healthcare Ventures. Inflammatix’s diagnostics rapidly read the patient’s immune response to infections across multiple mRNA biomarkers using machine learning algorithms. The company’s tests can identify the presence and type of infection (viral or bacterial), and the risk of severe disease, including severe COVID-19, to enable physicians to make more informed decisions. The funds will enable regulatory clearance and global commercialization of the Myrna system, and the InSep™ acute infection and sepsis test, which is designed to enable improved triage and decision-making in the emergency department and other acute care settings. 

    Related contacts

    Frederick Dorey
    Special Counsel, Palo Alto
    Anita Vasudevan
    Special Counsel, Palo Alto

    Related Practices & Industries

    Life Sciences and Healthcare
    Emerging Companies
    Venture Capital

  • Iconic Therapeutics Series C Financing

    • Iconic Therapeutics Series C Financing

    January 13, 2016

    Cooley advised Iconic Therapeutics on the closing of its $40 million Series C financing. The round included new investors HBM Healthcare Investments, Cormorant Asset Management and Osage University Partners. All of Iconic's existing investors, including MPM Capital, H.I.G. Capital and Lundbeck fund Ventures, participated in the round.

    According to Iconic, proceeds from the financing will be used to advance development of lead molecule ICON-1 in retinal diseases as well as begin clinical trials in ocular melanoma, Iconic's first oncology indication.

    Iconic is a clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor biology into new therapeutics for retinal disease and cancer.

    The team advising Iconic included Mark Weeks, Anita Vasudevan, Daniel Elefant, Mike Tuscan and Marya Postner.

    Related contacts

    Mark Weeks
    Partner, Palo Alto
    Anita Vasudevan
    Special Counsel, Palo Alto
    Dr. Michael Tuscan
    Partner, Washington, DC
    Marya Postner
    Partner, Palo Alto

    Related Practices & Industries

    Venture Capital
    Emerging Companies

  • IDEV Technologies $310 Million Acquisition by Abbott Labs

    • IDEV Technologies $310 Million Acquisition by Abbott Labs

    July 17, 2013

    Palo Alto, Calif. – Cooley represented IDEV Technologies in its $310 million acquisition by Abbott Laboratories. IDEV is a privately-held company focused on developing next-generation medical devices for use by interventional radiologists, vascular surgeons and cardiologists. Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. The transaction is expected to close by the end of 2013.

    Related contacts

    Mark Weeks
    Partner, Palo Alto
    Mark Windfeld-Hansen
    Senior Counsel, Palo Alto
    Natasha Leskovsek
    Of Counsel, Washington, DC
    Kevin King
    Partner, Washington, DC
    Anita Vasudevan
    Special Counsel, Palo Alto
    Sharon Connaughton
    Special Counsel, Washington, DC

  • Triphase Accelerator Corporation in its Partnership and Option-to-acquire Arrangement with Celgene

    • Triphase Accelerator Corporation in its Partnership and Option-to-acquire Arrangement with Celgene

    September 2, 2019

    Cooley advised Triphase Accelerator Corporation in its partnership and option-to-acquire arrangement with Celgene to advance a pre-clinical therapeutic developed to treat leukemia and other blood cancers. Under the terms of the agreement, Triphase received an upfront payment of $40 million and, upon exercise of the option, will be eligible to receive up to $940 million in contingent development, regulatory and sales milestones.

    Related contacts

    Marya Postner
    Partner, Palo Alto
    Anita Vasudevan
    Special Counsel, Palo Alto
    Lauren Creel
    Partner, Palo Alto
    Allison Pang
    Associate, Palo Alto

    Related Practices & Industries

    Life Sciences Corporate Partnering and Licensing

  • BrightFarms Closes $100 Million Series E

    • BrightFarms Closes $100 Million Series E

    November 12, 2020

    Cooley advised BrightFarms on its $100 million Series E financing. Partner Mark Medearis led the Cooley team advising BrightFarms, which is a leading next-generation indoor farming company supplying U.S. grocery retailers with packaged salad greens.

    Related contacts

    Mark Medearis
    Senior Counsel, Palo Alto
    Anita Vasudevan
    Special Counsel, Palo Alto
    Kris Tamashiro
    Paralegal Specialist, Palo Alto
    Howard Morse
    Senior Counsel, Washington, DC
    Megan Browdie
    Partner, Washington, DC
    Julia R. Brinton
    Special Counsel, Washington, DC

    Related Practices & Industries

    Emerging Companies
    Venture Capital
    Agricultural Sciences and Technology
View more

Admissions and credentials

  • California

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.